Financial Data and Key Metrics Changes - As of September 30, 2024, the company ended the quarter with $118 million in cash, cash equivalents, and investments, down from $137 million at the end of the second quarter [19] - Revenue for the third quarter was $33.4 million, an increase from $26.4 million in the same quarter of 2023, primarily driven by research collaborations with Bristol-Myers Squibb and Moderna [20] - Operating expenses for the third quarter were $29.3 million, an increase of $6.1 million compared to the third quarter of 2023, with R&D expenses rising to $21.4 million [20][21] Business Line Data and Key Metrics Changes - The company has three programs in Phase 1 clinical development: CX-904, CX-2051, and CX-801, with significant progress reported in each [4][5] - CX-904, a Probody T-cell engager, is currently in dose escalation, with a favorable safety profile and encouraging early signs of anticancer activity [7] - CX-2051, an antibody drug conjugate targeting EpCAM, has shown excellent early progress in its Phase 1 study, with a favorable safety profile and rapid enrollment in dose escalation cohorts [14] Market Data and Key Metrics Changes - The company estimates approximately 300,000 EpCAM-positive addressable patients in the United States alone, indicating a significant market opportunity for CX-2051 [14] - The focus on high unmet needs in oncology, particularly for solid tumors, positions the company strategically within the competitive landscape [4][5] Company Strategy and Development Direction - The company aims to advance its multi-modality clinical pipeline towards value inflection, focusing on CX-904, CX-2051, and CX-801 [24] - The Probody platform and antibody masking technology are highlighted as key strategic interests, with ongoing collaborations with major pharmaceutical partners [23][24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the pipeline's potential to deliver multiple clinical readouts in 2025, which will inform later-stage development [24] - The company remains disciplined in capital allocation, focusing on delivering against clinical milestones in 2025 [18][22] Other Important Information - The company has received $10 million in preclinical milestones through its collaboration with Astellas and continues to receive R&D funding across various partnerships [21] - The management emphasized the importance of ongoing collaborations with partners like Amgen, Astellas, BMS, Moderna, and Regeneron [21] Q&A Session Summary Question: Update on CX-904 and Phase 1b decision timing - Management indicated that the decision for Phase 1b is contingent on completing dose escalation and optimizing the dosing schedule, emphasizing the importance of maximizing the dose for this drug [26][27] Question: Status of CX-2051 dose levels - Management confirmed that they are pleased with the early progress of CX-2051 and are currently at dose level 5, which aligns with their safety and efficacy modeling [28] Question: Enrollment status for CX-904 in different tumor types - Management reported ongoing enrollment in pancreatic cancer and increased emphasis on head and neck and lung cancer, with plans to continue dose escalation [30][31] Question: Monotherapy vs. combination studies for CX-904 - Management stated that the current focus is on monotherapy in the Phase 1a setting, with potential consideration for combination strategies in future phases [33] Question: Enrollment criteria for CX-2051 - Management clarified that for colorectal cancer, they do not expect to select patients based on EpCAM expression due to its high prevalence, while other tumor types may require selection based on their assays [36][37] Question: Potential tumor types for CX-2051 - Management discussed the design of CX-2051 and its potential effectiveness across various tumor types, emphasizing the importance of the payload and linker in achieving therapeutic success [40][42] Question: Update on CX-904 data release timeline - Management confirmed that the next update on CX-904 will be next year, focusing on continued dose escalation and collaboration with Amgen [44]

CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to earnings of $0.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 143.75%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.07 per share when it actually produced a loss of $0.08, delivering a surprise of -14.29%.Over the la ...

- Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager) continues to advance. Potential Phase 1b initiation in 2025. - - Phase 1 study of CX-2051 (EpCAM PROBODY® ADC) in advanced colorectal cancer (CRC) is currently in the fifth dose escalation cohort. Initial data anticipated in the first half of 2025. - - Phase 1 study of CX-801 (interferon alpha-2b PROBODY® cytokine) as monotherapy and in combination with KEYTRUDA® is ongoing with a primary focus in melanoma. Initial data anticipated in ...

Exhibit 99.1 1 CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager) continues to advance. Potential Phase 1b initiation in 2025. - - Phase 1 study of CX-2051 (EpCAM PROBODY® ADC) in advanced colorectal cancer (CRC) is currently in the fifth dose escalation cohort. Initial data anticipated in the first half of 2025. - - Phase 1 study of CX-801 (interferon alpha-2b PROBODY® cytokine) as monotherap ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ | --- | --- | --- | |--------------------------------------------------------------------------------------------------------------|--------------- ...

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that the first patient has been dosed with CX-801 monotherapy in a Phase 1 study (NCT06462794) in patients with solid tumors. CX-801 is a dually-masked interferon alpha-2b PROBODY® cytokine with potential broad applicability in both traditionally immune-oncology sensitive as well as insensitive (cold) tumors. ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Chris Ogden - Chief Financial Officer Sean McCarthy - Chief Executive Officer and Chairman Wayne Chu - Chief Medical Officer Conference Call Participants Etzer Darout - BMO Capital Markets Malcolm Kuno - JPM Operator Good afternoon, everyone. Thank you for standing by and welcome to the CytomX Therapeutics Second Quarter 2024 Financial Results Call. Please be advised that today's call is b ...

Exhibit 99.1 CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - CX-904 (EGFR-CD3 PROBODY® T-cell engager) Phase 1a enrollment continues, primarily focused in PDAC, NSCLC, and HNSCC. Program update expected by the end of 2024 - - Phase 1 clinical study of CX-2051, an EpCAM targeting PROBODY® ADC, is ongoing. Study is currently enrolling third cohort with enrollment focused primarily in colorectal cancer (CRC); initial data anticipated in the first half of 2025 - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ | --- | --- | |-------------------------------------------------------------------------------------------------|-------------------------------| | Comm ...

SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024, at 2:00 p.m. ET. About CytomX Therapeutics A live webcast of the presentation will be available on the Event ...